SCHEMBL48377

SCHEMBL48377

COc1ccc(-c2sc(N)nc2C)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 2/20 0.62
KDM4E B2RXH2 5/20 0.60
PKM P14618 1/20 0.60
MAPT P10636 8/20 0.57
ALDH1A1 P00352 7/20 0.57
HSD17B10 Q99714 4/20 0.57
MEN1 O00255 4/20 0.57
GAA P10253 4/20 0.57
KMT2A Q03164 4/20 0.57
NPC1 O15118 3/20 0.57
TDP1 Q9NUW8 3/20 0.57
TSHR P16473 2/20 0.57
SMN1; SMN2 Q16637 4/20 0.53
NPSR1 Q6W5P4 2/20 0.53
MAPK1 P28482 2/20 0.53
LMNA P02545 1/20 0.53
XBP1 P17861 1/20 0.53
RAB9A P51151 3/20 0.51
POLB P06746 2/20 0.51
TP53 P04637 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8067414 0.84 MAPT (0.69) KDM4EPKMMAPTALDH1A1HSD17B10
Hydrochloric Acid SCHEMBL9548025 0.83 KDM4E (0.67) KDM4EPKMMAPTALDH1A1HSD17B10
SCHEMBL327676 0.82 ALOX5 (0.66) ALOX5KDM4EMAPTALDH1A1MEN1
SCHEMBL12943394 0.82 MAPT (0.70) ALOX5KDM4EMAPTALDH1A1HSD17B10
SCHEMBL5046972 0.81 MAPT (0.57) KDM4EMAPTALDH1A1HSD17B10MEN1
SCHEMBL16669665 0.79 ALDH1A1 (0.75) ALOX5KDM4EPKMMAPTALDH1A1
SCHEMBL28357165 0.79 SMN1; SMN2 (0.55) KDM4EPKMMAPTALDH1A1HSD17B10
SCHEMBL28127303 0.79 MAPT (0.53) KDM4EMAPTALDH1A1HSD17B10MEN1
SCHEMBL330449 0.79 MAPT (0.53) ALOX5KDM4EMAPTALDH1A1HSD17B10
SCHEMBL1747883 0.78 ALDH1A1 (0.63) ALOX5KDM4EPKMMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2311818-B1 Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug NOVARTIS AG (CH) 2013-01-16 EP disclosed
US-8129541-B2 5-phenylthiazole derivatives and use as PI3 kinase inhibitors NOVARTIS AG (CH) 2012-03-06 US disclosed
EP-1480962-B1 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS NOVARTIS AG (CH) 2011-08-24 EP disclosed
EP-2311818-A1 Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug Novartis AG (CH) 2011-04-20 EP disclosed
US-20100093690-A1 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS BRUCE IAN 2010-04-15 US disclosed
US-7687637-B2 5-phenylthiazole derivatives and use as Pi3 kinase inhibitors NOVARTIS AG (CH) 2010-03-30 US disclosed
US-20050119320-A1 5-phenylthiazole derivatives and use as pi3 kinase inhibitors NOVARTIS AG (CH) 2005-06-02 US disclosed
EP-1480962-A1 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS Novartis AG (CH) 2004-12-01 EP disclosed
WO-2003072557-A1 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS NOVARTIS AG (CH) 2003-09-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093690-A1 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS PIK3CA, PIK3R5, PIP5K1B ALOX5 2593/4885KDM4E 967/4885PKM 621/4885
US-20050119320-A1 5-phenylthiazole derivatives and use as pi3 kinase inhibitors PIK3CA, PIK3R5, PIP5K1B ALOX5 2593/4885KDM4E 967/4885PKM 621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.